| Aspect | Key points | Representative recent evidence (2024) and foundational evidence |
|---|---|---|
| Identity / domains | Human **CASP9** encodes **caspase-9**, the canonical **initiator caspase** of intrinsic (mitochondrial) apoptosis. Domain architecture matches UniProt P55211: **N-terminal CARD** plus catalytic caspase large/small subunits (p35/p10 after processing). Activation occurs on the **Apaf-1 apoptosome** via CARD–CARD interactions. | 2024 review and pathway synthesis support intrinsic-pathway initiator role; foundational apoptosome review details CARD-mediated recruitment to Apaf-1 apoptosome (pqac-00000006, pqac-00000007) |
| Catalytic reaction | **Cysteine-aspartate protease** that cleaves peptide bonds **C-terminal to Asp (P1 = D)** in substrates. Physiologic role is proteolytic activation of downstream effector caspases. | Caspases cleave after Asp; caspase-9 functions upstream of caspase-3/-7 (pqac-00000014, pqac-00000017) |
| Substrate specificity | Canonical peptide preference includes **LEHD**; deep profiling found a related **LESD↓(G/S)** motif in native lysates. Specificity depends on both sequence and local structural context. | LEHD-AFC described as optimal peptide substrate; N-terminomics identified LESD-like motif and lower catalytic efficiency than caspase-3 (pqac-00000012, pqac-00000016, pqac-00000017) |
| Activation mechanism | Mitochondrial stress releases **cytochrome c**, which binds **Apaf-1**; with nucleotide loading this forms the heptameric **apoptosome** that recruits procaspase-9 via CARD–CARD interactions, promoting dimerization/activation. Apoptosome binding strongly enhances productive processing of physiologic substrates. | 2024 intrinsic-apoptosis reviews summarize cytochrome c/Apaf-1/caspase-9 axis; foundational work shows apoptosome is the activating platform and optimizes procaspase-3 processing (pqac-00000006, pqac-00000007, pqac-00000012, pqac-00000016) |
| Key substrates | Best-established physiologic substrates are **procaspase-3** and **procaspase-7**. Caspase-9 directly cleaves procaspase-3 at the ISL motif **IETD↓S** (around D175) but does **not** directly activate procaspase-6 efficiently because local context blocks productive cleavage. Additional reported substrates include vimentin, semaphorin-7A, MVP, SNX1/2, HDAC7, RING2/RING1B, and many newly identified targets. | Procaspase-3 cleavage motif and inability to directly activate procaspase-6 shown biochemically; broader substrate set expanded by deep substrate profiling (pqac-00000011, pqac-00000013, pqac-00000014, pqac-00000018) |
| Regulation / PTMs | Caspase-9 is heavily regulated by phosphorylation and protein inhibitors. **c-Abl phosphorylation at Tyr-397** inhibits activity by blocking substrate binding near the active site. A 2024 study showed **LegK3** from *Legionella pneumophila* phosphorylates **Thr102** in caspase-9, impairing upstream processing/activation without abolishing intrinsic catalytic competence. **XIAP** is a direct endogenous inhibitor of caspase-9 and can restrain downstream activation after MOMP. | 2024 bacterial-effector study identifies **Thr102**; foundational JBC study identifies inhibitory **Tyr-397** phosphorylation; 2024 hepatocyte study notes XIAP directly inhibits caspase-9/3 downstream of MOMP (pqac-00000009, pqac-00000010, pqac-00000012) |
| Non-apoptotic roles | Beyond apoptosis, caspase-9 has reported roles in cell differentiation, mitochondrial/homeostatic regulation, and cell motility. In 2024 proteomics-based work, caspase-9 was identified as a **positive regulator of osteoblastic cell migration**. | 2024 osteoblast study supports migration role; multimodal review summarizes broader non-apoptotic functions (pqac-00000006, pqac-00000019) |
| Disease links | Dysregulated CASP9 signaling is implicated across cancer and neurodegeneration; Open Targets lists associations including **neurodegenerative disease**, **non-small cell lung carcinoma**, **acute myeloid leukemia**, and **hepatocellular carcinoma**. CASP9 alternative splicing into pro-apoptotic **caspase-9a** and pro-survival **caspase-9b** is a recurrent disease-relevant mechanism. | 2024 disease-focused reviews discuss oncologic and neurodegenerative relevance; Open Targets disease associations support broad translational importance; 2024 splicing review notes caspase-9a vs caspase-9b (pqac-00000000, pqac-00000006) |
| Applications / real-world implementation | **Inducible caspase-9 (iCasp9)** is an established **suicide/safety switch** in engineered cell therapy. A chemical dimerizer (e.g., **AP1903/rimiducid**) activates iCasp9, rapidly triggering apoptosis of modified cells to control **GVHD**, **CRS**, or **ICANS**. Representative trials: **NCT00710892** (CASPALLO allodepleted donor T cells; actual enrollment 10), **NCT01494103** (donor T cells with iCasp9 after haploidentical transplant; actual enrollment 15), **NCT03696784** (anti-CD19 CAR-T with iC9 safety switch for B-cell lymphoma; active-not-recruiting). | 2024 review summarizes iCasp9 mechanism, rapid kill kinetics, benefits and caveats; trial records document real clinical deployment in transplant and CAR-T settings (pqac-00000019, pqac-00000024, pqac-00000025, pqac-00000022, pqac-00000020) |


*Table: This table summarizes the core functional annotation of human CASP9/caspase-9, including mechanism, substrate specificity, regulation, disease relevance, and translational applications. It highlights both recent 2024 findings and foundational mechanistic evidence with citation IDs for direct traceability.*